Weekly Pharma & Life Science News Round-Up: 7th November – 11th November
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 7th-11th November.
Singleron Biotechnologies is happy to announce the opening of their brand-new laboratories in Cologne, Germany, dedicated to showcasing their vast single cell sequencing solutions, from instruments to novel kits tailored for many different research applications.
Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S.
Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its investment into neuroscience company NRG Therapeutics as part of its £16m (AUD$29m) series A financing.
Bayer announces the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) uses novel systems biology and computational life science tools to identify new modes of action for crop protection compounds.
Medvantx launches Medvantx Insights, a fully integrated, non-commercial pharmacy platform, and announced executive leadership expansions to further its mission to advance medication and healthcare access to individuals throughout the country.
Charles River Laboratories International, Inc. (NYSE: CRL) announces the expansion of its cell therapy contract development and manufacturing (CDMO) facility in Memphis, Tenn.
EdiGene, Inc. announces its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass. to advance proprietary LEAPER™ technology into transformative in vivo RNA editing therapies with an initial focus on ophthalmology and the CNS.
Aptar Pharma announces a collaboration with TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform.
Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, announces proceeds of $118 million in connection with the issuance of Series B preferred shares.
EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry, once again has been recognized globally as a Great Place to Work® by the leading authority in workplace culture.
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announces that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million.
Quanticate, a global data-focused clinical research organisation (CRO), has announced plans for further expansion and new jobs in 2023 as it thrives post-pandemic.
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities.
Minoryx Therapeutics and the Neuraxpharm Group (“Neuraxpharm”), a leading European speciality pharmaceutical company focused on CNS therapies, today announce the completion of a strategic license agreement.
Codetta® Biosciences announceds that the North Carolina Collaboratory has awarded Codetta and North Carolina Central University (NCCU) a $2 million research and development grant, aimed to dramatically impact COVID related research and future clinical care.